DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers
DataMEDS AI announced that its Helomics subsidiary received a Humana Medicaid coverage determination for the ChemoFx Assay in gynecologic cancers, billed under CPT codes 81535 and 81536, effective July 22, 2026. The policy covers testing for indications including rare cancers, initial biopsy or surgery, recurrent, treatment-refractory, or treatment-intolerant patients, though the assay is not covered under all Humana plans.
Key figures
- Drug Name
- ChemoFx Assay
- Cpt codes
- ["81535","81536"]
- Policy number
- HUM-SC-2240-003
- Cost assay adherent
- $23,986
- Cost assay assisted
- $33,187
- Policy effective date
- July 22, 2026
- Cost empiric treatment
- $48,758
- Icer recurrent eoc per ly
- $6,206
- Icer platinum resistant per ly
- $2,736
- Icer platinum sensitive per ly
- $2,773
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.